Maybe it has something to do with the time difference in Europe.
On Friday, Spain's Grifols issued a press release confirming that on Wednesday it completed its $4 billion acquisition of Talecris Biotherapeutics. Employees, Wall Street investors and just about anyone else who cared, of course, knew it was a done deal two days ago.
Next week, CEO Victor Grifols is scheduled to visit the Triangle to meet with his newest employees: Talecris' more than 2,000 local workers. They'll be eager to hear his plans to combine the companies. The acquisition is expected to spur job cuts, as Grifols consolidates operations to boost profits.
There's some consolation. Most Talecris employees received shares in the company's Sept. 2009 initial public offering, when the stock started trading at $19.